Indication
Clostridium difficile infection recurrence
8 clinical trials
11 products
Product
VE303Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VE303 for Prevention of Recurrent Clostridioides Difficile InfectionStatus: Not yet recruiting, Estimated PCD: 2027-06-01
Product
PlaceboProduct
RBX2660Clinical trial
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile InfectionStatus: Recruiting, Estimated PCD: 2025-01-16
Clinical trial
CONSORTIUM - A Double-Blind Placebo-Controlled Phase 2 Study of VE303 for Prevention of Recurrent Clostridium (Clostridioides) Difficile InfectionStatus: Completed, Estimated PCD: 2021-06-02
Clinical trial
A Randomized, Placebo-Controlled, Double-Blind, Phase 1 Study of ART24 in Subjects Recently Cured of a Clostridioides Difficile Infection (CDI)Status: Completed, Estimated PCD: 2022-07-07
Product
ART24Product
Full Spectrum MicrobiotaClinical trial
A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrence of Clostridium Difficile InfectionStatus: Completed, Estimated PCD: 2020-02-28
Clinical trial
Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant RecipientsStatus: Completed, Estimated PCD: 2023-06-01
Product
FMTProduct
VancomycinProduct
FMT oral placeboProduct
Oral VancomycinClinical trial
A Randomized, Double-Blinded Placebo Controlled Study To Determine the Effectiveness of Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)Status: Terminated, Estimated PCD: 2022-06-11
Clinical trial
Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile InfectionStatus: Completed, Estimated PCD: 2023-02-22
Product
BezlotoxumabProduct
Standard CDI